title: An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine.
abstract: Over the past two decades, there has been a notable rise in the use of antipsychotic drugs, as they are used to treat an increasing number of neuropsychiatric disorders. This rise has been led predominantly by greater use of the second generation antipsychotic (SGA) drugs, which have a low incidence of neurological side-effects. However, many SGAs cause metabolic dysregulation, including glucose intolerance and insulin resistance, thus increasing the risk of cardiometabolic disorders. The metabolic effects of the novel SGA lurasidone, which was approved by the Food and Drug Administration in 2010, remain largely unknown. As rodent models accurately predict the metabolic effects of SGAs in humans, the aim of the present study was to use sophisticated animal models of glucose tolerance and insulin resistance to measure the metabolic effects of lurasidone. In parallel, we compared the SGA olanzapine, which has established metabolic effects. Adult female rats were treated with vehicle, lurasidone (0.2, 0.8 or 2.0 mg/kg, s.c.) or olanzapine (10.0 mg/kg, s.c.) and subjected to the glucose tolerance test (GTT). Separate groups of rats were treated with vehicle, lurasidone (0.2, 0.8 or 2.0 mg/kg, s.c.) or olanzapine (1.5 and 15 mg/kg, s.c.) and tested for insulin resistance with the hyperinsulinemic-euglycemic clamp (HIEC). Compared to vehicle treated animals, lurasidone caused mild glucose intolerance in the GTT with a single dose, but there was no effect on insulin resistance in the GTT, measured by HOMA-IR. The HIEC also confirmed no effect of lurasidone on insulin resistance. In contrast, olanzapine demonstrated dose-dependent and potent glucose intolerance, and insulin resistance in both tests. Thus, in preclinical models, lurasidone demonstrates mild metabolic liability compared to existing SGAs such as olanzapine. However, confirmation of these effects in humans with equivalent tests should be confirmed.
authors.affiliation: Department of Pharmacology, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Claire
authors.initials: C
authors.lastname: Wu
authors.affiliation: Department of Pharmacology, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Jessica
authors.initials: J
authors.lastname: Yuen
authors.affiliation: Department of Pharmacology, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Heidi N
authors.initials: HN
authors.lastname: Boyda
authors.affiliation: Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada; British Columbia Mental Health and Addictions Research Institute, Vancouver, British Columbia, Canada.
authors.forename: Ric M
authors.initials: RM
authors.lastname: Procyshyn
authors.affiliation: Department of Pharmacology, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Cathy K
authors.initials: CK
authors.lastname: Wang
authors.affiliation: Department of Pharmacology, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Yahya I
authors.initials: YI
authors.lastname: Asiri
authors.affiliation: Department of Pharmacology, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Catherine C Y
authors.initials: CC
authors.lastname: Pang
authors.affiliation: Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada; British Columbia Mental Health and Addictions Research Institute, Vancouver, British Columbia, Canada.
authors.forename: William G
authors.initials: WG
authors.lastname: Honer
authors.affiliation: Department of Pharmacology, University of British Columbia, Vancouver, British Columbia, Canada; British Columbia Mental Health and Addictions Research Institute, Vancouver, British Columbia, Canada.
authors.forename: Alasdair M
authors.initials: AM
authors.lastname: Barr
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001569:Benzodiazepines / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005951:Glucose Tolerance Test; D007333:Insulin Resistance; D054833:Isoindoles / Q000494:pharmacology*; D000069056:Lurasidone Hydrochloride; D000077152:Olanzapine; D051381:Rats; D017207:Rats, Sprague-Dawley; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D014150:Antipsychotic Agents; D054833:Isoindoles; D013844:Thiazoles; D001569:Benzodiazepines; D000077152:Olanzapine; D000069056:Lurasidone Hydrochloride